Author: Leah Kosyakovsky

Novel siRNA targeting therapy lepodisiran results in a dose-dependent and sustained reduction in Lipoprotein(a)
AHA 2023, Lipid Lowering Therapy, News

Novel siRNA targeting therapy lepodisiran results in a dose-dependent and sustained reduction in Lipoprotein(a)

Key Points: There are currently no approved targeted therapies for the reduction of Lp(a). In this Phase I study, a novel siRNA therapy (lepodisiran) was tested... Read more.